It’s all about Big Data in Hematology.
Your Big Data!

HARMONY is ready to collect data and deliver outcomes
A unique European Network of Excellence for Big Data in Hematology

First IMI project on BD4BO for Hematologic Malignancies (HMs)

Open project: EU Cooperative Groups and Hospitals welcome

Stakeholders involvement: Academia, Industry, Payers, HTA, Regulators and Patients

First and largest Public-Private partnership (PPP) in hematology

High-quality HARMONY Big Data platform to include and harmonize data on Hematological Malignancies

Increase the application of omics data in clinical practice

Speed up drug development, access pathways and bench-to-bedside process

53 Public-Private Partners from 11 European countries.
Involving every stakeholder group to meet patients' needs.

Focus on 7 HM diseases: AML Acute Myeloid Leukemia . ALL Acute Lymphoblastic Leukemia . CLL Chronic Lymphocytic Leukemia . MDS Myelodysplastic Syndrome . MM Multiple Myeloma . NHL Non-Hodgkin Lymphoma. Pediatric HMs.
HARMONY – First 18 months

- Project launch Jan 2017
- 2nd General Assembly Oct 2017
- One year milestone Jan 2018
- EHA congress Jun 2018

We have grown in number!

- 51 partners
- 15 associated members
- 53 partners
  + 1 public
  + 1 private
- 24 associated members
HARMONY – First 18 months

We have achieved significant milestones

- Project launch: Jan 2017
- 2nd General Assembly: Oct 2017
- SOPs for the approval of bench-to-bedside research proposals
- Associated Members’ Engagement Framework and Data Sharing Agreements
- Platform ready for Data-Intake
- One year milestone: Jan 2018
- Communication & Dissemination activities
- Core outcome set definition for HMs started & ongoing
- Green light to legal framework & de-facto anonymization process from External Law Firm
- EHA congress: Jun 2018

Associated Members’ Engagement Framework and Data Sharing Agreements

We have achieved significant milestones
HARMONY – First 18 months

Bench-to-bedside projects ready to start!

AML (and APL)

2nd General Assembly Oct 2017

One year milestone Jan 2018

EHA congress Jun 2018

CLL

MM

“Bench-to-Bedside” Projects

Project launch Jan 2017

First data transfer to database expected in coming weeks!
Roadmap to the 3rd General Assembly

Incorporating the first datasets to the platform

Starting the analysis phase of the pilot studies

Access to Industry structure & data

Funded by
More achievements coming…

Data Analytics
Evidence and Value Framework
Continue defining a Standard Set of Outcomes
New project proposals
Modeling & Machine Learning
HARMONY is aimed at the entire haematological community!

- **We are an open project**
  - More than a 100 European organisations have shown their interest in HARMONY: co-operative Working Groups, Hospitals, Academic Institutions...
  - 80 institutions are in the process of becoming HARMONY Associated Members
  - Apart from our 53 partners, we already count with 24 Associated Members.

- **Your data are crucial!**
  - All of you are invited to join the HARMONY Alliance as Associated Members!
  - Help us meet the needs of patients with HMs.
This material is developed by the HARMONY Alliance

Disclaimer

This presentation is of scientific nature and has been produced by the HARMONY Alliance.

The HARMONY Alliance makes no warranties or representations of any kind as to the content's accuracy, currency or completeness, neither the Alliance nor any party involved in creating, producing or delivering this document shall be liable for any damages, including without limitation, direct, incidental, consequential, indirect or punitive damages, arising out of access to, use of or inability to use this document, or any errors or omissions in the content thereof. This material may not be used for commercial purposes. Remixing is not permitted except for private use.

Acknowledgement

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under HARMONY Grant Agreement n°116026. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Programme and EFPIA.